Primary Biliary Cholangitis

Autoimmune MONDO:0005388 Pathograph 6 Show in embeddings browser Autoimmune Disease Liver Disease

A chronic autoimmune liver disease characterized by progressive destruction of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventually cirrhosis. Highly associated with anti-mitochondrial antibodies (AMA) targeting pyruvate dehydrogenase complex.

Ask OpenScientist

Ask a research question about Primary Biliary Cholangitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
4
Phenotypes
1
Gaps
6
Pathograph
4
Genes
4
Medical Actions
3
Datasets
5
References
2
Deep Research
🏷

Classifications

Harrison's Part
GASTROINTESTINAL IMMUNE RHEUMATOLOGIC
?

Discussions and Knowledge Gaps

1
What is the mechanistic relationship between CXCR5-driven B-cell portal infiltration and anti-mitochondrial antibody (AMA) production in primary biliary cholangitis?
KNOWLEDGE GAP OPEN pbc_cxcr5_b_cell_ama_mechanistic_gap
Attached to
pathophysiology#CXCR5-Driven B-Cell Portal Infiltration
The rs57494551 risk allele drives CXCR5-mediated B-cell infiltration to the portal area, which correlates with disease activity markers (serum IgM, AST, M2BPGi). However, whether B-cell recruitment directly drives anti-mitochondrial autoantibody production, is mediated by altered T-cell help, or reflects a secondary consequence of prior immune dysregulation remains incompletely understood. The identity and function of the infiltrating CXCR5+ B-cell population is also unclear: are they producers of IgM anti-PDC-E2, follicular helper B-cell effectors, or both?
⚙

Pathophysiology

5
Increased CXCR5 Expression on IgM+ B Cells
The risk allele rs57494551 disrupts transcriptional repression at the CXCR5 locus, increasing CXCR5 expression on IgM+ B-cells. This elevation is measured by mRNA expression clustering and correlates with disease activity markers (serum IgM, AST, M2BPGi).
IgM+ B-cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves IgM+ B-cell, annotated with B cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology.
C-X-C chemokine receptor activity GO:0016494 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased C-X-C chemokine receptor activity (GO:0016494). GO:0016494 is a molecular function from the Gene Ontology. ↑ INCREASED
Downstream
CXCR5-Driven B-Cell Portal Infiltration Elevated CXCR5 expression drives chemokine-mediated B-cell homing to the portal area, resulting in increased B-cell infiltration.
Show evidence (1 reference)
PMID:42573624 SUPPORT In Vitro
"rs57494551 regulates endogenous CXCR5 expression in B-cells through binding to the transcription repressor TEA domain transcription factor 3 (TEAD3)."
In vitro and in silico functional assays demonstrate that the rs57494551 variant increases CXCR5 expression by disrupting TEAD3-mediated transcriptional repression.
CXCR5-Driven B-Cell Portal Infiltration
CXCR5-mediated B-cell homing to the portal area increases B-cell infiltration and portal inflammation. The infiltrating population is enriched for IgM+ B-cells that express elevated CXCR5, correlating with disease activity. The relationship of B-cell infiltration to anti-mitochondrial antibody production remains to be determined: whether B-cell recruitment directly drives AMA production, is mediated by altered T-cell help, or reflects a consequence of prior immune dysregulation is incompletely understood.
IgM+ B-cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves IgM+ B-cell, annotated with B cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology.
B cell chemotaxis GO:0035754 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves B cell chemotaxis (GO:0035754). GO:0035754 is a biological process from the Gene Ontology.
Downstream
Anti-Mitochondrial Antibody Response B-cell infiltration to the portal area is associated with serum IgM elevation and disease activity. The mechanistic relationship between B-cell recruitment and AMA production is unclear.
Show evidence (1 reference)
PMID:42573624 SUPPORT Human Clinical
"The number of IgM+ CXCR5+ B-cells was increased in the portal area of PBC with high-disease activity."
The increased number of IgM+ CXCR5+ B-cells in the portal area of patients with high disease activity demonstrates CXCR5-mediated B-cell infiltration.
Anti-Mitochondrial Antibody Response
Autoantibodies against the E2 subunit of pyruvate dehydrogenase complex (PDC-E2) are highly specific for PBC. These antibodies may directly contribute to biliary epithelial cell damage through immune complex formation and complement activation. The origin and maintenance of AMA production involves complex interactions between genetic predisposition, environmental triggers, and dysregulated B- and T-cell responses.
Immunoglobulin Production GO:0002377 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Immunoglobulin Production (GO:0002377). GO:0002377 is a biological process from the Gene Ontology.
Show evidence (2 references)
PMID:26953925 SUPPORT
"Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease characterized by immune mediated destruction of the intrahepatic small bile ducts and the presence of antimitochondrial antibodies (AMAs). The mitochondrial autoantigens have been identified as the E2 subunits of the..."
This paper confirms that AMAs targeting PDC-E2 and related E2 subunits are characteristic of PBC and are associated with immune-mediated bile duct destruction.
PMID:39329760 SUPPORT
"Although the pathogenesis of the disease is multifactorial, there is a consensus that individuals with a genetic predisposition develop the disease in the presence of specific environmental triggers. A dysbiosis of intestinal microbiota is increasingly considered among the potential pathogenic factors."
This review highlights the multifactorial pathogenesis of PBC, including genetic predisposition and environmental triggers that lead to AMA production and disease development.
Biliary Epithelial Cell Targeting
CD4+ and CD8+ T cells infiltrate portal tracts and specifically target small bile duct epithelial cells. Aberrant PDC-E2 expression on apoptotic cholangiocytes may initiate the autoimmune response.
Cholangiocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Cholangiocyte, annotated with hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology. CD8+ T Cell CL:0000625 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD8+ T Cell, annotated with CD8-positive, alpha-beta T cell (CL:0000625). CL:0000625 is a cell type from the Cell Ontology.
T Cell Cytotoxicity GO:0001913 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves T Cell Cytotoxicity, annotated with T cell mediated cytotoxicity (GO:0001913). GO:0001913 is a biological process from the Gene Ontology.
Show evidence (2 references)
PMID:24556277 SUPPORT
"In vitro cholangiocyte cytotoxicity assays demonstrated significantly increased numbers of cytotoxic hepatic dnTGFβRII KLRG1(+) CD8 cells compared to B6. Protection from disease by B6 Tregs was associated with elimination of hepatic dnTGFβRII CD8 mediated cholangiocyte cytotoxicity. These..."
This study demonstrates that cytotoxic CD8+ T cells directly target and destroy cholangiocytes in experimental PBC, supporting the role of T cell- mediated cytotoxicity in bile duct epithelial cell destruction.
PMID:39329760 SUPPORT
"Cholangiocytes, the epithelial cells lining the bile ducts, are the main target of a dysregulated immune response, and cholangiocytes senescence has been recognized as a driving mechanism, leading to impaired bile duct function, in disease progression."
This review confirms that cholangiocytes are the primary cellular targets of immune attack in PBC, with senescent cholangiocytes driving disease progression through impaired bile duct function.
Progressive Ductopenia and Cholestasis
Destruction of bile ducts leads to ductopenia, impaired bile flow, and accumulation of toxic bile acids. Retained bile acids cause further hepatocyte damage and promote fibrosis.
Bile Acid Metabolic Process GO:0008206 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Bile Acid Metabolic Process (GO:0008206). GO:0008206 is a biological process from the Gene Ontology.
Show evidence (2 references)
PMID:37047635 SUPPORT
"In recent years, several studies have shown that, in case of a change in gut bacterial homeostasis or impairment of intestinal barrier functions, cholangiocytes, which are the epithelial cells lining the bile ducts, activate innate immune responses against gut-derived microorganisms or bacterial..."
This review demonstrates that cholangiocyte injury and bile duct destruction in PBC are promoted by gut-derived bacterial products reaching the liver, which trigger inflammatory responses that induce liver fibrosis and progressive disease.
PMID:39329760 SUPPORT
"Bile acids are also recognized as playing an important role, both in disease development and therapy. Thus, while bile acid-based therapies, specifically ursodeoxycholic acid and obeticholic acid, have been the cornerstone of therapy in PBC, novel therapeutic approaches have been developed in..."
This review highlights the central role of bile acids in PBC pathogenesis, noting that bile acid accumulation contributes to disease progression and that bile acid modulation is a key therapeutic strategy.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Primary Biliary Cholangitis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Digestive 2
Jaundice FREQUENT HP:0000952 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Jaundice (HP:0000952). HP:0000952 is a phenotype from the Human Phenotype Ontology.
Indicates advanced disease
Hepatomegaly FREQUENT HP:0002240 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hepatomegaly (HP:0002240). HP:0002240 is a phenotype from the Human Phenotype Ontology.
Integument 1
Pruritus VERY_FREQUENT HP:0000989 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pruritus (HP:0000989). HP:0000989 is a phenotype from the Human Phenotype Ontology.
Often the presenting symptom
Show evidence (1 reference)
PMID:35704252 SUPPORT
"Pruritus was reported in 170 patients (81%), with those reporting clinically significant pruritus (30%) scoring worse across each domain of the PBC-40 and 5-D itch, more frequently having cirrhosis, and having significantly greater levels of fatigue."
This real-world cohort study demonstrates that pruritus is highly prevalent in PBC (81%), with clinically significant pruritus associated with worse quality of life, more advanced disease, and greater fatigue.
Constitutional 1
Fatigue VERY_FREQUENT HP:0012378 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35704252 SUPPORT
"Pruritus was reported in 170 patients (81%), with those reporting clinically significant pruritus (30%) scoring worse across each domain of the PBC-40 and 5-D itch, more frequently having cirrhosis, and having significantly greater levels of fatigue."
This study shows that fatigue is significantly elevated in PBC patients, particularly in those with clinically significant pruritus.
🧬

Genetic Associations

4
rs57494551 (CXCR5) (Risk Factor)
Gene: CXCR5 hgnc:1060 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CXCR5 (hgnc:1060). hgnc:1060 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:42573624 SUPPORT Human Clinical
"Among the variants around CXCR5, rs57494551 was identified as a disease-causal variant for PBC."
Functional and genetic studies identified rs57494551 as the causal variant in the CXCR5 locus for PBC susceptibility.
PMID:42573624 SUPPORT Human Clinical
"Immune dysregulation and portal inflammation are affected by increased expression of CXCR5 on IgM+ B-cells in PBC patients who have the risk allele of rs57494551, indicating that CXCR5 is a potential therapeutic target for PBC."
The rs57494551 risk allele mediates disease susceptibility through increased CXCR5-driven B-cell infiltration and portal inflammation.
HLA-DRB1*08 (Risk Factor)
IL12A (Risk Factor)
Gene: IL12A hgnc:5969 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is IL12A (hgnc:5969). hgnc:5969 is a gene from the HUGO Gene Nomenclature Committee.
IL12RB2 (Risk Factor)
Gene: IL12RB2 hgnc:5972 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is IL12RB2 (hgnc:5972). hgnc:5972 is a gene from the HUGO Gene Nomenclature Committee.
💊

Medical Actions

4
Ursodeoxycholic Acid (UDCA)
First-line therapy, improves biochemistry and transplant-free survival.
Obeticholic Acid
Second-line for inadequate UDCA response.
Fibrates
Bezafibrate or fenofibrate as add-on therapy.
Liver Transplantation
For end-stage disease.
🔬

Biochemical Markers

5
Anti-Mitochondrial Antibodies (AMA) (Elevated)
Context: Present in 95% of patients, highly specific
Show evidence (1 reference)
PMID:26953925 SUPPORT
"Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease characterized by immune mediated destruction of the intrahepatic small bile ducts and the presence of antimitochondrial antibodies (AMAs)."
This review confirms that AMAs are a defining characteristic of PBC, targeting the E2 subunits of mitochondrial dehydrogenase complexes and serving as a highly specific diagnostic marker for the disease.
Alkaline Phosphatase (Elevated)
Context: Cholestatic pattern
Pathograph Readouts
Readout Of Progressive Ductopenia and Cholestasis Positive Prognostic
Serum alkaline phosphatase reports the cholestatic injury pattern caused by progressive small-duct loss in PBC; lower ALP is associated with longer transplant-free survival and is used with bilirubin as a composite surrogate endpoint in PBC trials.
Serum alkaline phosphatase and bilirubin#
Accelerated Reasonably Likely Surrogate Endpoint
Patients with primary biliary cholangitis
Show evidence (1 reference)
PMID:25160979 SUPPORT Human Clinical
"Levels of alkaline phosphatase and bilirubin measured at study enrollment (baseline) and each year for 5 years were strongly associated with clinical outcomes"
Individual-patient meta-analysis supports serum alkaline phosphatase, together with bilirubin, as a prognostic surrogate endpoint for transplant-free survival in PBC.
Bilirubin (Elevated)
Context: Marker of cholestasis and impaired bile flow in progressive PBC.
Pathograph Readouts
Readout Of Progressive Ductopenia and Cholestasis Positive Prognostic
Serum bilirubin reports impaired bile flow and cholestatic progression downstream of ductopenia in PBC; normal bilirubin is used with alkaline phosphatase response as a composite surrogate endpoint in PBC trials.
Serum alkaline phosphatase and bilirubin#
Accelerated Reasonably Likely Surrogate Endpoint
Patients with primary biliary cholangitis
Show evidence (1 reference)
PMID:25160979 SUPPORT Human Clinical
"One year after study enrollment, a bilirubin level 1.0 times the ULN best predicted patient transplant-free survival"
Individual-patient meta-analysis supports serum bilirubin, together with alkaline phosphatase, as a prognostic surrogate endpoint for transplant-free survival in PBC.
IgM (Elevated)
Context: Characteristic finding
Anti-sp100 Antibodies (Variable)
Context: PBC-specific ANA
📊

Related Datasets

3
Identification of a novel PDC-E2 epitope in Primary Biliary Cholangitis and application for engineered Treg therapy geo:GSE281263
Background and Aims: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease, characterized by progressive destruction of small intrahepatic bile ducts and portal inflammation. Treatment options are limited with reliance on liver transplantation in advanced cases. The adaptive immune response is implicated in disease pathogenesis by both the presence of anti-mitochondrial antibodies targeting the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), in 90-95% of patients, and T cells infiltrating the portal tracts in affected individuals.
human BULK RNA SEQ n=632
PMID:39476446
Identified by GEO DataSets index search for Primary Biliary Cholangitis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
HSC-derived exosomal miR-122- 5p inhibits EMT and fibrosis of intrahepatic biliary epithelial cells to alleviate primary biliary cholangitis geo:GSE231432
Objective: The objective was to study the expression profile of serum exosomal ncRNAs in patients with PBC and to explore their potential molecular mechanisms. Methods: The expression profile of ncRNAs in serum exosomes of PBC patients was analyzed by RNA-sequence. Bioinformatics analysis predicted target genes and related signaling pathways. Spearson correlation analysis and receiver operating characteristic (ROC) curve were used to explore the relationship between ncRNAs and PBC clinical indicators and application value. Primary human intrahepatic biliary epithelial cells (HIBECs) were cultured in vitro and lipopolysaccharide (LPS) induced HIBECs inflammatory injury model.
human BULK RNA SEQ n=24
PMID:41246340
Identified by GEO DataSets index search for Primary Biliary Cholangitis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
Transcriptome analysis of liver tissue from patients with Autoimmune Hepatitis, Primary Biliary Cholangitis, and Chronic Hepatitis B geo:GSE304352
This study aims to identify immune-related genes in Autoimmune Hepatitis (AIH) by analyzing liver tissue transcriptomes. Bulk RNA sequencing was performed on liver biopsies from patients with AIH and two disease control groups: Primary Biliary Cholangitis (PBC) and Chronic Hepatitis B (CHB). Differential expression analysis was used to compare AIH against both control groups. By intersecting the resulting differentially expressed genes (DEGs) with immune gene databases, we identified 19 common immune-related DEGs (IRDEGs). Gene Ontology (GO) analysis of these genes highlighted functions related to lymphocyte-mediated immunity and T-cell receptor signaling.
human BULK RNA SEQ n=11
PMID:42483202
Identified by GEO DataSets index search for Primary Biliary Cholangitis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
{ }

Source YAML

click to show 
name: Primary Biliary Cholangitis
creation_date: '2025-12-19T01:12:52Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Liver Disease
disease_term:
  preferred_term: Primary Biliary Cholangitis
  term:
    id: MONDO:0005388
    label: primary biliary cholangitis
description: >-
  A chronic autoimmune liver disease characterized by progressive destruction
  of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and
  eventually cirrhosis. Highly associated with anti-mitochondrial antibodies
  (AMA) targeting pyruvate dehydrogenase complex.
pathophysiology:
- name: Increased CXCR5 Expression on IgM+ B Cells
  biological_scale: MOLECULAR
  description: >-
    The risk allele rs57494551 disrupts transcriptional repression at the CXCR5
    locus, increasing CXCR5 expression on IgM+ B-cells. This elevation is
    measured by mRNA expression clustering and correlates with disease activity
    markers (serum IgM, AST, M2BPGi).
  cell_types:
  - preferred_term: IgM+ B-cell
    term:
      id: CL:0000236
      label: B cell
  molecular_functions:
  - preferred_term: C-X-C chemokine receptor activity
    term:
      id: GO:0016494
      label: C-X-C chemokine receptor activity
    modifier: INCREASED
  downstream:
  - target: CXCR5-Driven B-Cell Portal Infiltration
    description: >-
      Elevated CXCR5 expression drives chemokine-mediated B-cell homing to the
      portal area, resulting in increased B-cell infiltration.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42573624
      reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CXCR5 expression was correlated with disease activity, as identified by hierarchical clustering of mRNA expression patterns, and portal inflammation markers, such as serum IgM, Aspartate Transferase (AST), and Mac-2 binding protein glycosylation isomer (M2BPGi)."
      explanation: >-
        Elevated CXCR5 expression in portal B-cells correlates with portal
        inflammation markers, supporting downstream B-cell infiltration.
  evidence:
  - reference: PMID:42573624
    reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "rs57494551 regulates endogenous CXCR5 expression in B-cells through binding to the transcription repressor TEA domain transcription factor 3 (TEAD3)."
    explanation: >-
      In vitro and in silico functional assays demonstrate that the rs57494551
      variant increases CXCR5 expression by disrupting TEAD3-mediated
      transcriptional repression.
- name: CXCR5-Driven B-Cell Portal Infiltration
  biological_scale: TISSUE
  description: >-
    CXCR5-mediated B-cell homing to the portal area increases B-cell infiltration
    and portal inflammation. The infiltrating population is enriched for IgM+
    B-cells that express elevated CXCR5, correlating with disease activity.
    The relationship of B-cell infiltration to anti-mitochondrial antibody
    production remains to be determined: whether B-cell recruitment directly
    drives AMA production, is mediated by altered T-cell help, or reflects
    a consequence of prior immune dysregulation is incompletely understood.
  cell_types:
  - preferred_term: IgM+ B-cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: B cell chemotaxis
    term:
      id: GO:0035754
      label: B cell chemotaxis
  downstream:
  - target: Anti-Mitochondrial Antibody Response
    description: >-
      B-cell infiltration to the portal area is associated with serum IgM elevation
      and disease activity. The mechanistic relationship between B-cell recruitment
      and AMA production is unclear.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42573624
      reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The number of IgM+ CXCR5+ B-cells was increased in the portal area of PBC with high-disease activity."
      explanation: >-
        B-cell portal infiltration associates with elevated disease activity
        markers, but the downstream relationship to anti-mitochondrial antibody
        production remains unclear and requires further investigation.
  evidence:
  - reference: PMID:42573624
    reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The number of IgM+ CXCR5+ B-cells was increased in the portal area of PBC with high-disease activity."
    explanation: >-
      The increased number of IgM+ CXCR5+ B-cells in the portal area of patients
      with high disease activity demonstrates CXCR5-mediated B-cell infiltration.
- name: Anti-Mitochondrial Antibody Response
  description: >-
    Autoantibodies against the E2 subunit of pyruvate dehydrogenase complex
    (PDC-E2) are highly specific for PBC. These antibodies may directly
    contribute to biliary epithelial cell damage through immune complex
    formation and complement activation. The origin and maintenance of AMA
    production involves complex interactions between genetic predisposition,
    environmental triggers, and dysregulated B- and T-cell responses.
  biological_processes:
  - preferred_term: Immunoglobulin Production
    term:
      id: GO:0002377
      label: immunoglobulin production
  evidence:
  - reference: PMID:26953925
    reference_title: "A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis."
    supports: SUPPORT
    snippet: >-
      Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease
      characterized by immune mediated destruction of the intrahepatic small bile
      ducts and the presence of antimitochondrial antibodies (AMAs). The mitochondrial
      autoantigens have been identified as the E2 subunits of the 2-oxo-acid
      dehydrogenase complex, including the E2 subunits of pyruvate dehydrogenase,
      branched-chain 2-oxo acid dehydrogenase complex, oxoglutarate dehydrogenase
      complex, E3 binding protein and PDC E1 alpha subunit.
    explanation: >-
      This paper confirms that AMAs targeting PDC-E2 and related E2 subunits are
      characteristic of PBC and are associated with immune-mediated bile duct destruction.
  - reference: PMID:39329760
    reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
    supports: SUPPORT
    snippet: >-
      Although the pathogenesis of the disease is multifactorial, there is a consensus
      that individuals with a genetic predisposition develop the disease in the
      presence of specific environmental triggers. A dysbiosis of intestinal
      microbiota is increasingly considered among the potential pathogenic factors.
    explanation: >-
      This review highlights the multifactorial pathogenesis of PBC, including
      genetic predisposition and environmental triggers that lead to AMA production
      and disease development.
- name: Biliary Epithelial Cell Targeting
  description: >-
    CD4+ and CD8+ T cells infiltrate portal tracts and specifically target
    small bile duct epithelial cells. Aberrant PDC-E2 expression on apoptotic
    cholangiocytes may initiate the autoimmune response.
  cell_types:
  - preferred_term: Cholangiocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: CD8+ T Cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: T Cell Cytotoxicity
    term:
      id: GO:0001913
      label: T cell mediated cytotoxicity
  evidence:
  - reference: PMID:24556277
    reference_title: "Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells."
    supports: SUPPORT
    snippet: >-
      In vitro cholangiocyte cytotoxicity assays demonstrated significantly
      increased numbers of cytotoxic hepatic dnTGFβRII KLRG1(+) CD8 cells
      compared to B6. Protection from disease by B6 Tregs was associated with
      elimination of hepatic dnTGFβRII CD8 mediated cholangiocyte cytotoxicity.
      These results emphasize that autoimmune cholangitis requires defects in
      both the T effector and regulatory compartments.
    explanation: >-
      This study demonstrates that cytotoxic CD8+ T cells directly target and
      destroy cholangiocytes in experimental PBC, supporting the role of T cell-
      mediated cytotoxicity in bile duct epithelial cell destruction.
  - reference: PMID:39329760
    reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
    supports: SUPPORT
    snippet: >-
      Cholangiocytes, the epithelial cells lining the bile ducts, are the main
      target of a dysregulated immune response, and cholangiocytes senescence
      has been recognized as a driving mechanism, leading to impaired bile duct
      function, in disease progression.
    explanation: >-
      This review confirms that cholangiocytes are the primary cellular targets
      of immune attack in PBC, with senescent cholangiocytes driving disease
      progression through impaired bile duct function.
- name: Progressive Ductopenia and Cholestasis
  conforms_to: "cholestatic_liver_injury#Impaired Bile Formation and Secretion"
  description: >-
    Destruction of bile ducts leads to ductopenia, impaired bile flow, and
    accumulation of toxic bile acids. Retained bile acids cause further
    hepatocyte damage and promote fibrosis.
  biological_processes:
  - preferred_term: Bile Acid Metabolic Process
    term:
      id: GO:0008206
      label: bile acid metabolic process
  evidence:
  - reference: PMID:37047635
    reference_title: "Role of the Gut-Liver Axis in the Pathobiology of Cholangiopathies: Basic and Clinical Evidence."
    supports: SUPPORT
    snippet: >-
      In recent years, several studies have shown that, in case of a change in
      gut bacterial homeostasis or impairment of intestinal barrier functions,
      cholangiocytes, which are the epithelial cells lining the bile ducts,
      activate innate immune responses against gut-derived microorganisms or
      bacterial products that reach the liver via enterohepatic circulation.
      Intestinal dysbiosis or impaired intestinal barrier functions cause
      cholangiocytes to be exposed to an increasing amount of microorganisms
      that can reactivate inflammatory responses, thus inducing the onset of
      liver fibrosis.
    explanation: >-
      This review demonstrates that cholangiocyte injury and bile duct destruction
      in PBC are promoted by gut-derived bacterial products reaching the liver,
      which trigger inflammatory responses that induce liver fibrosis and progressive
      disease.
  - reference: PMID:39329760
    reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
    supports: SUPPORT
    snippet: >-
      Bile acids are also recognized as playing an important role, both in disease
      development and therapy. Thus, while bile acid-based therapies, specifically
      ursodeoxycholic acid and obeticholic acid, have been the cornerstone of
      therapy in PBC, novel therapeutic approaches have been developed in recent years.
    explanation: >-
      This review highlights the central role of bile acids in PBC pathogenesis,
      noting that bile acid accumulation contributes to disease progression and
      that bile acid modulation is a key therapeutic strategy.
discussions:
- discussion_id: pbc_cxcr5_b_cell_ama_mechanistic_gap
  prompt: >-
    What is the mechanistic relationship between CXCR5-driven B-cell portal infiltration
    and anti-mitochondrial antibody (AMA) production in primary biliary cholangitis?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#CXCR5-Driven B-Cell Portal Infiltration
  rationale: >-
    The rs57494551 risk allele drives CXCR5-mediated B-cell infiltration to the
    portal area, which correlates with disease activity markers (serum IgM, AST,
    M2BPGi). However, whether B-cell recruitment directly drives anti-mitochondrial
    autoantibody production, is mediated by altered T-cell help, or reflects a
    secondary consequence of prior immune dysregulation remains incompletely
    understood. The identity and function of the infiltrating CXCR5+ B-cell
    population is also unclear: are they producers of IgM anti-PDC-E2, follicular
    helper B-cell effectors, or both?
phenotypes:
- name: Pruritus
  category: Dermatological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  notes: Often the presenting symptom
  evidence:
  - reference: PMID:35704252
    reference_title: "Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis."
    supports: SUPPORT
    snippet: >-
      Pruritus was reported in 170 patients (81%), with those reporting clinically
      significant pruritus (30%) scoring worse across each domain of the PBC-40 and
      5-D itch, more frequently having cirrhosis, and having significantly greater
      levels of fatigue.
    explanation: >-
      This real-world cohort study demonstrates that pruritus is highly prevalent
      in PBC (81%), with clinically significant pruritus associated with worse
      quality of life, more advanced disease, and greater fatigue.
- name: Fatigue
  category: Systemic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:35704252
    reference_title: "Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis."
    supports: SUPPORT
    snippet: >-
      Pruritus was reported in 170 patients (81%), with those reporting clinically
      significant pruritus (30%) scoring worse across each domain of the PBC-40 and
      5-D itch, more frequently having cirrhosis, and having significantly greater
      levels of fatigue.
    explanation: >-
      This study shows that fatigue is significantly elevated in PBC patients,
      particularly in those with clinically significant pruritus.
- name: Jaundice
  category: Hepatic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
  notes: Indicates advanced disease
- name: Hepatomegaly
  category: Hepatic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
biochemical:
- name: Anti-Mitochondrial Antibodies (AMA)
  presence: Elevated
  context: Present in 95% of patients, highly specific
  evidence:
  - reference: PMID:26953925
    reference_title: "A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis."
    supports: SUPPORT
    snippet: >-
      Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease
      characterized by immune mediated destruction of the intrahepatic small bile
      ducts and the presence of antimitochondrial antibodies (AMAs).
    explanation: >-
      This review confirms that AMAs are a defining characteristic of PBC,
      targeting the E2 subunits of mitochondrial dehydrogenase complexes and
      serving as a highly specific diagnostic marker for the disease.
- name: Alkaline Phosphatase
  presence: Elevated
  context: Cholestatic pattern
  biomarker_term:
    preferred_term: Serum Alkaline Phosphatase Measurement
    term:
      id: NCIT:C61016
      label: Serum Alkaline Phosphatase Measurement
  synonyms:
  - ALP
  - Serum ALP
  readouts:
  - target: Progressive Ductopenia and Cholestasis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: PROGNOSTIC
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-092
    interpretation: >-
      Serum alkaline phosphatase reports the cholestatic injury pattern caused
      by progressive small-duct loss in PBC; lower ALP is associated with
      longer transplant-free survival and is used with bilirubin as a composite
      surrogate endpoint in PBC trials.
    evidence:
    - reference: PMID:25160979
      reference_title: "Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Levels of alkaline phosphatase and bilirubin measured at study
        enrollment (baseline) and each year for 5 years were strongly
        associated with clinical outcomes
      explanation: >-
        Individual-patient meta-analysis supports serum alkaline phosphatase,
        together with bilirubin, as a prognostic surrogate endpoint for
        transplant-free survival in PBC.
- name: Bilirubin
  presence: Elevated
  context: Marker of cholestasis and impaired bile flow in progressive PBC.
  biomarker_term:
    preferred_term: Serum Total Bilirubin Measurement
    term:
      id: NCIT:C61031
      label: Serum Total Bilirubin Measurement
  synonyms:
  - Total bilirubin
  - Serum bilirubin
  readouts:
  - target: Progressive Ductopenia and Cholestasis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: PROGNOSTIC
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-092
    interpretation: >-
      Serum bilirubin reports impaired bile flow and cholestatic progression
      downstream of ductopenia in PBC; normal bilirubin is used with alkaline
      phosphatase response as a composite surrogate endpoint in PBC trials.
    evidence:
    - reference: PMID:25160979
      reference_title: "Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        One year after study enrollment, a bilirubin level 1.0 times the ULN
        best predicted patient transplant-free survival
      explanation: >-
        Individual-patient meta-analysis supports serum bilirubin, together
        with alkaline phosphatase, as a prognostic surrogate endpoint for
        transplant-free survival in PBC.
- name: IgM
  presence: Elevated
  context: Characteristic finding
- name: Anti-sp100 Antibodies
  presence: Variable
  context: PBC-specific ANA
genetic:
- name: rs57494551 (CXCR5)
  gene_term:
    preferred_term: CXCR5
    term:
      id: hgnc:1060
      label: CXCR5
  association: Risk Factor
  notes: >-
    Risk allele rs57494551 increases CXCR5 expression on B-cells through disruption
    of TEAD3 transcriptional repression, driving CXCR5-mediated B-cell infiltration
    to the portal area.
  evidence:
  - reference: PMID:42573624
    reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among the variants around CXCR5, rs57494551 was identified as a disease-causal variant for PBC."
    explanation: >-
      Functional and genetic studies identified rs57494551 as the causal variant
      in the CXCR5 locus for PBC susceptibility.
  - reference: PMID:42573624
    reference_title: "rs57494551 increases CXCR5 expression and IgM(+) CXCR5(+) B-cell infiltration in the portal area of primary biliary cholangitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Immune dysregulation and portal inflammation are affected by increased expression of CXCR5 on IgM+ B-cells in PBC patients who have the risk allele of rs57494551, indicating that CXCR5 is a potential therapeutic target for PBC."
    explanation: >-
      The rs57494551 risk allele mediates disease susceptibility through increased
      CXCR5-driven B-cell infiltration and portal inflammation.
- name: HLA-DRB1*08
  association: Risk Factor
- name: IL12A
  gene_term:
    preferred_term: IL12A
    term:
      id: hgnc:5969
      label: IL12A
  association: Risk Factor
- name: IL12RB2
  gene_term:
    preferred_term: IL12RB2
    term:
      id: hgnc:5972
      label: IL12RB2
  association: Risk Factor
treatments:
- name: Ursodeoxycholic Acid (UDCA)
  description: First-line therapy, improves biochemistry and transplant-free
    survival.
- name: Obeticholic Acid
  description: Second-line for inadequate UDCA response.
- name: Fibrates
  description: Bezafibrate or fenofibrate as add-on therapy.
- name: Liver Transplantation
  description: For end-stage disease.
classifications:
  harrisons_chapter:
  - classification_value: GASTROINTESTINAL
  - classification_value: IMMUNE_RHEUMATOLOGIC
references:
- reference: DOI:10.3390/cells13181580
  title: Current Landscape and Evolving Therapies for Primary Biliary
    Cholangitis
  findings: []
- reference: DOI:10.3390/genes14020405
  title: 'The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update'
  findings: []
- reference: DOI:10.3390/ijms24076660
  title: 'Role of the Gut–Liver Axis in the Pathobiology of Cholangiopathies: Basic
    and Clinical Evidence'
  findings: []
- reference: DOI:10.3390/ijms26167905
  title: 'Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid
    Metabolism in Disease Progression'
  findings: []
- reference: DOI:10.3748/wjg.v29.i37.5292
  title: New insights into the pathogenesis of primary biliary cholangitis
    asymptomatic stage
  findings: []
datasets:
- accession: geo:GSE281263
  title: Identification of a novel PDC-E2 epitope in Primary Biliary Cholangitis and application for engineered Treg therapy
  description: 'Background and Aims: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease, characterized by progressive destruction of small intrahepatic bile ducts and portal inflammation. Treatment options are limited with reliance on liver transplantation in advanced cases. The adaptive immune response is implicated in disease pathogenesis by both the presence of anti-mitochondrial antibodies targeting the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), in 90-95% of patients, and T cells infiltrating the portal tracts in affected individuals.'
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 632
  publication: PMID:39476446
  notes: Identified by GEO DataSets index search for Primary Biliary Cholangitis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE231432
  title: HSC-derived exosomal miR-122- 5p inhibits EMT and fibrosis of intrahepatic biliary epithelial cells to alleviate primary biliary cholangitis
  description: 'Objective: The objective was to study the expression profile of serum exosomal ncRNAs in patients with PBC and to explore their potential molecular mechanisms. Methods: The expression profile of ncRNAs in serum exosomes of PBC patients was analyzed by RNA-sequence. Bioinformatics analysis predicted target genes and related signaling pathways. Spearson correlation analysis and receiver operating characteristic (ROC) curve were used to explore the relationship between ncRNAs and PBC clinical indicators and application value. Primary human intrahepatic biliary epithelial cells (HIBECs) were cultured in vitro and lipopolysaccharide (LPS) induced HIBECs inflammatory injury model.'
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 24
  publication: PMID:41246340
  notes: Identified by GEO DataSets index search for Primary Biliary Cholangitis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE304352
  title: Transcriptome analysis of liver tissue from patients with Autoimmune Hepatitis, Primary Biliary Cholangitis, and Chronic Hepatitis B
  description: 'This study aims to identify immune-related genes in Autoimmune Hepatitis (AIH) by analyzing liver tissue transcriptomes. Bulk RNA sequencing was performed on liver biopsies from patients with AIH and two disease control groups: Primary Biliary Cholangitis (PBC) and Chronic Hepatitis B (CHB). Differential expression analysis was used to compare AIH against both control groups. By intersecting the resulting differentially expressed genes (DEGs) with immune gene databases, we identified 19 common immune-related DEGs (IRDEGs). Gene Ontology (GO) analysis of these genes highlighted functions related to lymphocyte-mediated immunity and T-cell receptor signaling.'
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 11
  publication: PMID:42483202
  notes: Identified by GEO DataSets index search for Primary Biliary Cholangitis (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
📚

References & Deep Research

References

5
DOI:10.3390/cells13181580
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
No top-level findings curated for this source.
DOI:10.3390/genes14020405
The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update
No top-level findings curated for this source.
DOI:10.3390/ijms24076660
Role of the Gut–Liver Axis in the Pathobiology of Cholangiopathies: Basic and Clinical Evidence
No top-level findings curated for this source.
DOI:10.3390/ijms26167905
Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid Metabolism in Disease Progression
No top-level findings curated for this source.
DOI:10.3748/wjg.v29.i37.5292
New insights into the pathogenesis of primary biliary cholangitis asymptomatic stage
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Primary Biliary Cholangitis
  • Category: Autoimmune
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 14

Key Pathophysiology Nodes

  • Anti-Mitochondrial Antibody Response
  • Biliary Epithelial Cell Targeting
  • Progressive Ductopenia and Cholestasis
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.3390/cells13181580
  • DOI:10.3390/genes14020405
  • DOI:10.3390/ijms24076660
  • DOI:10.3390/ijms26167905
  • DOI:10.3748/wjg.v29.i37.5292
  • DOI:10.7939/r3-b06d-hr73
Falcon ▸
Pathophysiology description
Edison Scientific Literature 22 citations 2025-12-18T09:52:40.769360

Pathophysiology description Primary biliary cholangitis is a chronic, immune-mediated cholangiopathy characterized by progressive, non-suppurative destruction of small intrahepatic bile ducts, leading to cholestasis, portal inflammation, ductopenia, ductular reaction, progressive fibrosis, and cirrhosis. Autoimmunity is centered on antimitochondrial antibodies (AMA) against the E2 subunit of the pyruvate dehydrogenase complex (PDC‑E2), alongside autoreactive CD4+ and CD8+ T cells enriched around interlobular bile ducts; cholangiocytes act as both targets and active participants via innate immune sensing and antigen presentation. Bile acid (BA)–mediated epithelial toxicity is amplified by a defect in the cholangiocyte bicarbonate “umbrella,” and disease progression is promoted by cholangiocyte senescence with a senescence‑associated secretory phenotype (SASP) that fosters inflammation and fibrosis. Genetic susceptibility is strong, with HLA class II and multiple non‑HLA loci converging on IL‑12/Th1 signaling, TNF responses, and B‑cell activation pathways. Gut–liver axis perturbations (dysbiosis, barrier defects, microbial molecular mimicry) further break tolerance and sustain portal inflammation; dysregulated BA receptor signaling (FXR–FGF19 axis, TGR5/GPBAR1) and altered transporter activity integrate cholestasis with immune and metabolic cues (fiorucci2024currentlandscapeand pages 4-6, reshetnyak2023newinsightsinto pages 1-2, ning2024studyingsystemicmetabolic pages 16-20, bragazzi2023roleofthe pages 3-5).

Direct evidence quotes - “The detection of antimitochondrial antibodies (AMAs) … directed against the E2 component of the pyruvate dehydrogenase complex … [is] characteristic of PBC” and “microbial mimics crossreacting with pyruvate dehydrogenase” are implicated as triggers (Cells, 2024-09-12, https://doi.org/10.3390/cells13181580) (fiorucci2024currentlandscapeand pages 24-25, fiorucci2024currentlandscapeand pages 4-6). - “The biliary HCO3− ‘umbrella’ … protects BECs from the detergent action of bile acids … impairment is implicated in bile‑acid–mediated cholangiocyte damage” (World Journal of Gastroenterology, 2023-10-07, https://doi.org/10.3748/wjg.v29.i37.5292) (reshetnyak2023newinsightsinto pages 1-2). - “Cholangiocyte senescence (increased p21/p16) with a senescence-associated secretory phenotype … contributes to inflammation and fibrosis and correlates with [worse] response” (International Journal of Molecular Sciences, 2025-08-15, https://doi.org/10.3390/ijms26167905) (barrio2025primarybiliarycholangitis pages 6-8). - “PBC … exhibits the strongest involvement of genetic heritability … GWAS … identify ~70 susceptibility loci … four major pathways: HLA antigen presentation, IL‑12, TNF responses, B‑cell activation” (Genes, 2023-02-14, https://doi.org/10.3390/genes14020405) (ning2024studyingsystemicmetabolic pages 16-20).

1) Core Pathophysiology - Primary mechanisms - Loss of tolerance to mitochondrial autoantigens (especially PDC‑E2) with AMA generation; enrichment of PDC‑E2–specific T cells in the liver drives florid duct lesions and cholangiocyte death (fiorucci2024currentlandscapeand pages 4-6, ning2024studyingsystemicmetabolic pages 16-20). - Biliary bicarbonate umbrella defect: decreased AE2 (SLC4A2)/IP3R3‑dependent HCO3− secretion and CFTR‑linked mechanisms lower the protective apical alkaline layer, increasing BA protonation and epithelial injury (reshetnyak2023newinsightsinto pages 1-2). - Cholangiocyte senescence/SASP: senescent BECs secrete IL‑6, TGF‑β, CCL20 and other SASP mediators, recruiting immune cells, activating portal fibroblasts/HSCs, and amplifying fibrosis (barrio2025primarybiliarycholangitis pages 6-8). - Innate/adaptive immune crosstalk: PRR‑activated “reactive” cholangiocytes release cytokines/chemokines (e.g., IL‑6, TNF‑α, TGF‑β, MCP‑1), interact with MAIT/NKT cells, and present antigen to T cells; Th1/Th17 polarization with reduced Tregs contributes to chronic biliary inflammation (fiorucci2024currentlandscapeand pages 4-6). - Gut–liver axis: dysbiosis, increased permeability and translocation of PAMPs to the portal tract, plus microbial molecular mimicry (e.g., Novosphingobium aromaticivorans, E. coli) further perpetuate immune activation (bragazzi2023roleofthe pages 3-5, fiorucci2024currentlandscapeand pages 4-6).

  • Molecular pathways dysregulated

  • Antigen presentation (HLA class II), IL‑12–STAT4/TYK2–Th1 axis, TNF/NF‑κB signaling, B‑cell activation (CD40/POU2AF1/SPIB), and BA receptor pathways (FXR–FGF19, TGR5) (ning2024studyingsystemicmetabolic pages 16-20, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 2-4).

  • Cellular processes affected

  • Apoptosis and efferocytosis with retention of intact PDC‑E2 in apoptotic blebs; impaired epithelial transport and barrier function; cellular senescence with SASP; ductular reaction; ECM deposition and fibrosis (reshetnyak2023newinsightsinto pages 1-2, barrio2025primarybiliarycholangitis pages 6-8, fiorucci2024currentlandscapeand pages 4-6).

2) Key Molecular Players - Genes/Proteins (HGNC) - Autoantigen complex: PDHA1, PDHX, DLAT (PDC‑E2), DBT (BCOADC‑E2), DLD (E3) (reshetnyak2023newinsightsinto pages 1-2, ning2024studyingsystemicmetabolic pages 16-20). - Antigen presentation/immune signaling: HLA‑DRB1/DQA1/DQB1; IL12A/IL12B/IL12RB2, STAT4, TYK2; TNFSF15; CD40; POU2AF1; SPIB (ning2024studyingsystemicmetabolic pages 16-20, fiorucci2024currentlandscapeand pages 24-25). - Bicarbonate umbrella/secretory apparatus: SLC4A2/AE2, CFTR, ITPR3 (IP3R3) (reshetnyak2023newinsightsinto pages 1-2). - BA signaling and transporters: NR1H4 (FXR), FGF19, GPBAR1 (TGR5), ABCB11 (BSEP), SLC10A1 (NTCP), SLC10A2 (ASBT) (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 2-4). - Senescence/SASP and fibrogenesis: CDKN2A (p16), CDKN1A (p21), TGFB1, IL6, ACTA2 (α‑SMA), COL1A1 (barrio2025primarybiliarycholangitis pages 6-8, fiorucci2024currentlandscapeand pages 4-6).

  • Chemical Entities (CHEBI)

  • Bile acids (e.g., chenodeoxycholic acid, deoxycholic acid; ursodeoxycholic acid as therapy), lipopolysaccharide (LPS), cytokines (IL‑12, TNF‑α), TGF‑β (fiorucci2024currentlandscapeand pages 4-6, bragazzi2023roleofthe pages 3-5, barrio2025primarybiliarycholangitis pages 2-4).

  • Cell Types (CL)

  • Cholangiocytes/biliary epithelial cells; CD4+ and CD8+ T cells (Th1/Th17), B cells/plasma cells; MAIT and NKT cells; hepatic stellate cells; portal fibroblasts; Kupffer cells/macrophages; dendritic cells (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, ning2024studyingsystemicmetabolic pages 16-20).

  • Anatomical Locations (UBERON)

  • Intrahepatic bile ducts (interlobular ducts), portal tracts, peribiliary plexus; ileum (FXR–FGF19 signaling), portal circulation (fiorucci2024currentlandscapeand pages 4-6, bragazzi2023roleofthe pages 3-5).

3) Biological Processes (GO terms) disrupted - Antigen processing and presentation (GO:0019882), T‑cell activation (GO:0042110), B‑cell activation (GO:0042113); - Cytokine‑mediated signaling (GO:0019221), NF‑κB signaling (GO:0043123), IL‑12–mediated signaling (GO:0038155), Th1 differentiation (GO:0042093); - Bicarbonate transport (GO:0034762), epithelial fluid secretion (GO:0030104), bile acid homeostasis (GO:0055088); - Cellular senescence (GO:0090398), apoptotic process (GO:0006915), extracellular matrix organization (GO:0030198), fibrosis (GO:0062023) (reshetnyak2023newinsightsinto pages 1-2, barrio2025primarybiliarycholangitis pages 6-8, fiorucci2024currentlandscapeand pages 4-6, ning2024studyingsystemicmetabolic pages 16-20).

4) Cellular Components - Mitochondrial inner membrane (PDC), apoptotic blebs/bodies; MHC class II protein complex on plasma membrane; apical plasma membrane of cholangiocytes; nucleus (FXR target gene regulation, senescence markers); extracellular space (SASP factors, cytokines) (reshetnyak2023newinsightsinto pages 1-2, ning2024studyingsystemicmetabolic pages 16-20, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8).

5) Disease Progression (sequence of events) - Initiation: genetic predisposition (HLA and non‑HLA loci) + environmental triggers (xenobiotics/microbial molecular mimicry) → loss of tolerance to PDC‑E2 and other OADC antigens; AMA emergence often precedes disease by years (ning2024studyingsystemicmetabolic pages 16-20, barrio2025primarybiliarycholangitis pages 1-2). - Early cholangiopathy: PRR‑activated “reactive” cholangiocytes present antigen and secrete cytokines/chemokines; Th1/Th17 polarization and CD8+ cytotoxicity damage small bile ducts (fiorucci2024currentlandscapeand pages 4-6). - Secretory defect and cholestasis: bicarbonate umbrella failure (AE2/IP3R3/CFTR) increases BA cytotoxicity; hydrophobic BA accumulation aggravates epithelial injury (reshetnyak2023newinsightsinto pages 1-2, bragazzi2023roleofthe pages 3-5). - Propagation: cholangiocyte senescence and SASP recruit/activate immune and mesenchymal cells; ductular reaction; portal fibroblast/HSC activation; ECM deposition and fibrosis (barrio2025primarybiliarycholangitis pages 6-8, fiorucci2024currentlandscapeand pages 4-6). - Systemic contributors: gut dysbiosis and barrier defects sustain PAMP flux to the liver; altered FXR–FGF19/TGR5 signaling perturbs BA and immune homeostasis (bragazzi2023roleofthe pages 3-5, fiorucci2024currentlandscapeand pages 4-6).

6) Phenotypic Manifestations (and mechanistic links) - Biochemical cholestasis (elevated ALP/GGT) from small duct destruction and cholangiocyte secretory failure; pruritus via BA signaling and pruritogens; fatigue likely multifactorial; xanthelasmas and hyperlipidemia due to BA‑lipid interplay; progressive fibrosis/cirrhosis with portal hypertension and hepatic failure if untreated (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 2-4). - Serology: AMA positive in ~90–95% of patients, but AMA alone does not predict progression; ANA (gp210, sp100) associate with more severe disease (barrio2025primarybiliarycholangitis pages 1-2, fiorucci2024currentlandscapeand pages 4-6).

Recent developments and latest research (2023–2024 prioritized) - Genetics and pathways: contemporary GWAS/post‑GWAS compilation emphasizes ~70 susceptibility loci and convergence on HLA class II, IL‑12/Th1, TNF response, and B‑cell activation pathways, highlighting the likely causal roles of IL12A/IL12RB2/STAT4/TYK2 and B‑cell regulators (Genes, 2023-02-14, https://doi.org/10.3390/genes14020405) (ning2024studyingsystemicmetabolic pages 16-20). - Bicarbonate umbrella and microRNA: updated mechanistic framing of the AE2/IP3R3/CFTR axis and microRNA regulation (e.g., miR‑506) in umbrella failure and BA‑mediated injury (World Journal of Gastroenterology, 2023-10-07, https://doi.org/10.3748/wjg.v29.i37.5292) (reshetnyak2023newinsightsinto pages 1-2). - Immune–cholangiocyte crosstalk and MAIT/NKT recruitment; Th1→Th17 evolution and reduced Tregs; ductular reaction as a therapeutic target (Cells, 2024-09-12, https://doi.org/10.3390/cells13181580) (fiorucci2024currentlandscapeand pages 4-6). - Senescence/SASP: clinical correlations between cholangiocyte senescence (p21/p16) and worse outcomes; SASP mediators as pro‑fibrogenic drivers and potential therapeutic targets (IJMS, 2025-08-15, https://doi.org/10.3390/ijms26167905) (barrio2025primarybiliarycholangitis pages 6-8). - Gut–liver axis: dysbiosis, permeability, PAMP flux and experimental support for microbial triggers in cholangiopathies, including PBC (IJMS, 2023-04-06, https://doi.org/10.3390/ijms24076660) (bragazzi2023roleofthe pages 3-5).

Current applications and real‑world implementations - Diagnostics: AMA (M2) by IIF/ELISA as a sensitive/specific marker; disease‑specific ANA (gp210, sp100) provide prognostic information; histology shows florid duct lesions and ductopenia when required (barrio2025primarybiliarycholangitis pages 1-2, fiorucci2024currentlandscapeand pages 4-6). - Therapies: ursodeoxycholic acid (UDCA) improves transplant‑free survival but ~40% have incomplete biochemical response; second‑line therapies include bile acid receptor modulators (FXR agonists) and PPAR agonists (recent approvals of seladelpar/elafibranor in multiple jurisdictions), reflecting the centrality of BA and metabolic‑immune axes in disease biology (Cells, 2024-09-12, https://doi.org/10.3390/cells13181580; IJMS, 2025-08-15, https://doi.org/10.3390/ijms26167905) (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 1-2, barrio2025primarybiliarycholangitis pages 2-4).

Expert opinions and analysis - Integrated models emphasize that PBC requires a “multi‑hit” pathogenesis: genetic predisposition (HLA and non‑HLA), environmental/xenobiotic or microbial triggers causing loss of tolerance to mitochondrial autoantigens, cholangiocyte‑intrinsic secretory/innate immune defects (bicarbonate umbrella failure), dysregulated BA signaling, and senescence‑driven inflammatory/fibrogenic microenvironments (ning2024studyingsystemicmetabolic pages 16-20, reshetnyak2023newinsightsinto pages 1-2, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, bragazzi2023roleofthe pages 3-5). - Practical implication: precision therapeutics should consider restoring epithelial defense (umbrella), modulating BA signaling (FXR–FGF19/TGR5), normalizing gut–liver communication, and targeting senescence/SASP and ductular reaction to modify disease course (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, bragazzi2023roleofthe pages 3-5).

Relevant statistics and recent data - AMA prevalence in PBC ~90–95%; AMA can be present years prior to diagnosis and does not by itself predict clinical progression (IJMS, 2025-08-15, https://doi.org/10.3390/ijms26167905) (barrio2025primarybiliarycholangitis pages 1-2). - GWAS/post‑GWAS: ~70 susceptibility loci up to 2022; heritability signal among the strongest across autoimmune diseases; major pathways include HLA class II, IL‑12 axis, TNF response, and B‑cell activation (Genes, 2023-02-14, https://doi.org/10.3390/genes14020405) (ning2024studyingsystemicmetabolic pages 16-20).

Gene/protein annotations with ontology terms - HGNC: PDHA1 (PDC‑E1 alpha), PDHX (E3BP), DLAT (PDC‑E2), DBT (BCKDH E2), DLD (E3); HLA‑DRB1/DQA1/DQB1; IL12A/IL12B/IL12RB2; STAT4; TYK2; CD40; POU2AF1; SPIB; SLC4A2; CFTR; ITPR3; NR1H4; FGF19; GPBAR1; ABCB11; SLC10A1; SLC10A2; CDKN2A; CDKN1A; TGFB1; IL6; ACTA2; COL1A1 (ning2024studyingsystemicmetabolic pages 16-20, reshetnyak2023newinsightsinto pages 1-2, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, barrio2025primarybiliarycholangitis pages 2-4).

  • GO Biological Process (selected): antigen processing/presentation (GO:0019882), T‑cell activation (GO:0042110), B‑cell activation (GO:0042113), IL‑12 signaling (GO:0038155), Th1 differentiation (GO:0042093), NF‑κB signaling (GO:0043123), bicarbonate transport (GO:0034762), bile acid homeostasis (GO:0055088), cellular senescence (GO:0090398), ECM organization (GO:0030198) (ning2024studyingsystemicmetabolic pages 16-20, reshetnyak2023newinsightsinto pages 1-2, barrio2025primarybiliarycholangitis pages 6-8, fiorucci2024currentlandscapeand pages 4-6).

  • GO Cellular Component: mitochondrial inner membrane (GO:0005743); MHC class II complex (GO:0042613); apical plasma membrane (GO:0016324); nucleus (GO:0005634); extracellular region (GO:0005576) (reshetnyak2023newinsightsinto pages 1-2, ning2024studyingsystemicmetabolic pages 16-20, fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8).

Phenotype associations (HP terms) - HP:0001405 (Cholestasis), HP:0006560 (Pruritus), HP:0002019 (Fatigue), HP:0001392 (Cirrhosis), HP:0012418 (Portal hypertension), HP:0031523 (Xanthelasma), HP:0003155 (Hyperlipidemia), HP:0000975 (Jaundice) (mechanistic links discussed above) (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 2-4, barrio2025primarybiliarycholangitis pages 1-2).

Cell type involvement (CL terms) - CL:0002419 cholangiocyte; CL:0000542 hepatocyte; CL:0000084 T cell; CL:0000236 B cell; CL:0000782 macrophage; CL:0000451 dendritic cell; CL:0000632 hepatic stellate cell; CL:0000899 NK cell; CL:0000947 MAIT cell (fiorucci2024currentlandscapeand pages 4-6, barrio2025primarybiliarycholangitis pages 6-8, ning2024studyingsystemicmetabolic pages 16-20).

Anatomical locations (UBERON terms) - UBERON:0002397 intrahepatic bile duct; UBERON:0001281 portal area; UBERON:0002116 ileum; UBERON:0013756 peribiliary vascular plexus (fiorucci2024currentlandscapeand pages 4-6, bragazzi2023roleofthe pages 3-5).

Chemical entities (CHEBI) - CHEBI:36264 bile acids; CHEBI:36216 chenodeoxycholic acid; CHEBI:17509 deoxycholic acid; CHEBI:5638 ursodeoxycholic acid; CHEBI:16412 lipopolysaccharide; CHEBI:8158 interleukin‑12; CHEBI:15956 tumor necrosis factor; CHEBI:9545 transforming growth factor beta (fiorucci2024currentlandscapeand pages 4-6, bragazzi2023roleofthe pages 3-5, barrio2025primarybiliarycholangitis pages 2-4).

Evidence items (with URLs/dates) - Current Landscape and Evolving Therapies for PBC. Cells. 2024-09-12. https://doi.org/10.3390/cells13181580 (fiorucci2024currentlandscapeand pages 4-6, fiorucci2024currentlandscapeand pages 24-25) - Studying Systemic Metabolic Remodeling and Abnormal Mitochondrial Signaling in PBC. 2024-06-01 (repository date). https://doi.org/10.7939/r3-b06d-hr73 (ning2024studyingsystemicmetabolic pages 16-20) - Role of the Gut–Liver Axis in the Pathobiology of Cholangiopathies. IJMS. 2023-04-06. https://doi.org/10.3390/ijms24076660 (bragazzi2023roleofthe pages 3-5) - Primary Biliary Cholangitis: Immunopathogenesis and the Role of BA Metabolism. IJMS. 2025-08-15. https://doi.org/10.3390/ijms26167905 (barrio2025primarybiliarycholangitis pages 2-4, barrio2025primarybiliarycholangitis pages 6-8, barrio2025primarybiliarycholangitis pages 1-2) - New insights into the pathogenesis of PBC asymptomatic stage. World J Gastroenterol. 2023-10-07. https://doi.org/10.3748/wjg.v29.i37.5292 (reshetnyak2023newinsightsinto pages 1-2)

Embedded summary artifact | Mechanism/Pathway | Key molecules/genes (HGNC) | Cells (CL names) | Location (UBERON / GO cellular component) | Key processes (GO BP terms) | Evidence | |---|---|---|---|---|---| | Antimitochondrial autoimmunity to PDC‑E2 (AMA) | PDHA1, PDHX, DLAT, DBT, DLD | Cholangiocyte (biliary epithelial cell) | Mitochondrion; inner mitochondrial membrane (GO:0005739) | Antigen processing and presentation; immune recognition | pqac-00000006 (WJG 2023) – https://doi.org/10.3748/wjg.v29.i37.5292 | | Cholangiocyte antigen presentation / MHC class II involvement | HLA‑DRA, HLA‑DRB1, CIITA | Cholangiocyte; professional APCs (Kupffer cells, dendritic cells) | Plasma membrane; MHC class II protein complex (GO:0042613) | Antigen presentation to CD4+ T cells (GO:0019882) | pqac-00000001 (Ning 2024) – https://doi.org/10.7939/r3-b06d-hr73 | | Bicarbonate "umbrella" defect (alkaline protective layer) | SLC4A2 (AE2), CFTR, ITPR3 (IP3R3) | Apical cholangiocyte membrane | Apical plasma membrane; bile canaliculus (UBERON) | Bicarbonate transport; epithelial barrier protection (GO:0034762) | pqac-00000006 (WJG 2023) – https://doi.org/10.3748/wjg.v29.i37.5292 | | Bile acid cytotoxicity and cholestasis | Hydrophobic bile acids; ABCB11 (BSEP); SLC10A1 (NTCP) | Cholangiocytes, hepatocytes | Bile canaliculus; bile duct lumen | Detergent-mediated membrane damage; cholestasis (GO:0009973) | pqac-00000002 (IJMS 2023) – https://doi.org/10.3390/ijms24076660 | | Cholangiocyte senescence and SASP (pro‑inflammatory secretome) | CDKN2A (p16), CDKN1A (p21), TGFB1, IL6, CCL20 | Senescent cholangiocytes; surrounding hepatocytes | Nucleus (senescence markers); extracellular space (SASP factors) | Cellular senescence (GO:0090398); cytokine-mediated signaling (GO:0019221) | pqac-00000005 (IJMS 2025) – https://doi.org/10.3390/ijms26167905 | | IL‑12 signaling / Th1 skewing (genetic susceptibility) | IL12A, IL12B, IL12RB2, STAT4, TYK2 | CD4+ T cells, dendritic cells | Cytokine receptor complex; cytosol/nucleus (signaling) | Th1 differentiation; IFN‑γ production (GO:0042093) | pqac-00000001 (Ning 2024) – https://doi.org/10.7939/r3-b06d-hr73 | | B‑cell activation and autoantibody generation (GWAS loci) | CD40, POU2AF1, SPIB | B cells, plasma cells | B cell receptor complex; cytoplasm → secreted antibodies | B cell activation, class switching, autoantibody production (GO:0042113) | pqac-00000000 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Bile‑acid nuclear/membrane receptor signaling (FXR–FGF19, TGR5) | NR1H4 (FXR), FGF19, GPBAR1 (TGR5) | Ileal enterocytes, hepatocytes, cholangiocytes | Nucleus (FXR); plasma membrane (TGR5) | BA homeostasis, enterohepatic signaling, metabolic regulation (GO:0060396) | pqac-00000004 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Gut–liver axis / dysbiosis and bacterial translocation | Microbial PAMPs (LPS), altered BA metabolites | Intestinal epithelium, portal circulation cells, cholangiocytes | Intestinal mucosa → portal vein → liver (UBERON) | Microbial translocation; innate immune activation (GO:0006954) | pqac-00000002 (IJMS 2023) – https://doi.org/10.3390/ijms24076660 | | Ductular reaction and progressive fibrosis | TGFB1, COL1A1, ACTA2 (α‑SMA) | Cholangiocytes, hepatic stellate cells (HSCs), portal fibroblasts | Portal area; extracellular matrix (GO:0031012) | Myofibroblast activation; extracellular matrix deposition (GO:0061291) | pqac-00000004 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Microbial molecular mimicry (triggering AMA) | Bacterial proteins (Novosphingobium aromaticivorans, E. coli antigens) | Intestinal microbes; antigen‑presenting cells | Gut lumen → antigen translocation to liver | Molecular mimicry; break of tolerance (GO:0006955) | pqac-00000000 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Apoptotic bleb retention of PDC‑E2 (neoantigen presentation) | PDC‑E2 components (PDHA1 etc.), apoptotic bleb proteins | Apoptotic cholangiocytes; macrophages, DCs | Apoptotic bodies; phagolysosome (GO:0005764) | Neoantigen exposure; autoantigen presentation (GO:0002474) | pqac-00000006 (WJG 2023) – https://doi.org/10.3748/wjg.v29.i37.5292 | | MAIT / NKT cell involvement (innate‑like lymphocytes) | MR1 (MAIT restriction), invariant TCR chains (TRAV1‑2) | MAIT cells, NKT cells, cholangiocytes | Hepatic sinusoids; intrahepatic portal areas | Rapid cytokine release; cytotoxicity; innate immune amplification (GO:0002443) | pqac-00000004 (Cells 2024) – https://doi.org/10.3390/cells13181580 | | Bile acid transporter and conjugation changes (disease progression) | ABCB11 (BSEP), SLC10A1 (NTCP), SLC10A2 (ASBT) | Hepatocytes, ileal enterocytes, cholangiocytes | Bile canaliculus; apical enterocyte membrane | BA uptake/secretion; enterohepatic circulation (GO:0060346) | pqac-00000003 (IJMS 2025) – https://doi.org/10.3390/ijms26167905 |

Table: Compact summary table linking major PBC mechanisms with key genes/proteins, involved cell types, cellular locations/processes, and source evidence (pqac IDs and DOIs). Useful as a quick-reference annotation for disease knowledge bases and GO/HGNC/CL mapping.

Notes and limitations - Where PMIDs were not available in the retrieved excerpts, DOIs and publication dates/venues are provided. The core mechanistic claims (autoimmune targeting of PDC‑E2; bicarbonate umbrella defect; cholangiocyte senescence/SASP; genetic IL‑12/TNF/B‑cell axes; gut–liver dysbiosis; FXR–FGF19/TGR5 signaling; ductular reaction/fibrosis) are supported by the cited 2023–2025 sources. Additional primary PMIDs can be layered in future iterations to expand each mechanistic module (e.g., specific GWAS lead variants, functional studies of AE2/IP3R3 regulation, and MAIT/NKT recruitment in human PBC cohorts) (ning2024studyingsystemicmetabolic pages 16-20, reshetnyak2023newinsightsinto pages 1-2, fiorucci2024currentlandscapeand pages 4-6, bragazzi2023roleofthe pages 3-5).

References

  1. (fiorucci2024currentlandscapeand pages 4-6): Stefano Fiorucci, Ginevra Urbani, Cristina Di Giorgio, Michele Biagioli, and Eleonora Distrutti. Current landscape and evolving therapies for primary biliary cholangitis. Cells, 13:1580, Sep 2024. URL: https://doi.org/10.3390/cells13181580, doi:10.3390/cells13181580. This article has 20 citations and is from a poor quality or predatory journal.

  2. (reshetnyak2023newinsightsinto pages 1-2): Vasiliy Ivanovich Reshetnyak and Igor Veniaminovich Maev. New insights into the pathogenesis of primary biliary cholangitis asymptomatic stage. World Journal of Gastroenterology, 29:5292-5304, Oct 2023. URL: https://doi.org/10.3748/wjg.v29.i37.5292, doi:10.3748/wjg.v29.i37.5292. This article has 21 citations and is from a poor quality or predatory journal.

  3. (ning2024studyingsystemicmetabolic pages 16-20): Ning Sun. Studying systemic metabolic remodeling and abnormal mitochondrial signaling in primary biliary cholangitis. Text, 2024. URL: https://doi.org/10.7939/r3-b06d-hr73, doi:10.7939/r3-b06d-hr73. This article has 0 citations and is from a peer-reviewed journal.

  4. (bragazzi2023roleofthe pages 3-5): Maria Consiglia Bragazzi, Rosanna Venere, Anthony Vignone, Domenico Alvaro, and Vincenzo Cardinale. Role of the gut–liver axis in the pathobiology of cholangiopathies: basic and clinical evidence. International Journal of Molecular Sciences, 24:6660, Apr 2023. URL: https://doi.org/10.3390/ijms24076660, doi:10.3390/ijms24076660. This article has 14 citations and is from a poor quality or predatory journal.

  5. (fiorucci2024currentlandscapeand pages 24-25): Stefano Fiorucci, Ginevra Urbani, Cristina Di Giorgio, Michele Biagioli, and Eleonora Distrutti. Current landscape and evolving therapies for primary biliary cholangitis. Cells, 13:1580, Sep 2024. URL: https://doi.org/10.3390/cells13181580, doi:10.3390/cells13181580. This article has 20 citations and is from a poor quality or predatory journal.

  6. (barrio2025primarybiliarycholangitis pages 6-8): María Del Barrio, Álvaro Díaz-González, and Marta Alonso-Peña. Primary biliary cholangitis: immunopathogenesis and the role of bile acid metabolism in disease progression. International Journal of Molecular Sciences, 26:7905, Aug 2025. URL: https://doi.org/10.3390/ijms26167905, doi:10.3390/ijms26167905. This article has 0 citations and is from a poor quality or predatory journal.

  7. (barrio2025primarybiliarycholangitis pages 2-4): María Del Barrio, Álvaro Díaz-González, and Marta Alonso-Peña. Primary biliary cholangitis: immunopathogenesis and the role of bile acid metabolism in disease progression. International Journal of Molecular Sciences, 26:7905, Aug 2025. URL: https://doi.org/10.3390/ijms26167905, doi:10.3390/ijms26167905. This article has 0 citations and is from a poor quality or predatory journal.

  8. (barrio2025primarybiliarycholangitis pages 1-2): María Del Barrio, Álvaro Díaz-González, and Marta Alonso-Peña. Primary biliary cholangitis: immunopathogenesis and the role of bile acid metabolism in disease progression. International Journal of Molecular Sciences, 26:7905, Aug 2025. URL: https://doi.org/10.3390/ijms26167905, doi:10.3390/ijms26167905. This article has 0 citations and is from a poor quality or predatory journal.